BerandaGRFS • NASDAQ
add
Grifols SA - ADR ADR Class B
$8,96
Setelah Jam Perdagangan Normal:(0,00%)0,00
$8,96
Tutup: 26 Feb, 16.35.26 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$9,25
Rentang hari
$8,28 - $9,20
Rentang tahun
$6,19 - $11,14
Kapitalisasi pasar
7,64 M USD
Volume Rata-Rata
490,34 rb
Rasio P/E
13,90
Hasil dividen
1,96%
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (EUR) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,87 M | 4,04% |
Biaya operasional | 370,34 jt | -1,71% |
Penghasilan bersih | 126,96 jt | 145,62% |
Margin laba bersih | 6,81 | 136,46% |
Penghasilan per saham | — | — |
EBITDA | 484,03 jt | 3,41% |
Tarif pajak efektif | 27,61% | — |
Neraca
Total aset
Total liabilitas
| (EUR) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 825,48 jt | 2,32% |
Total aset | 19,85 M | -2,12% |
Total liabilitas | 12,31 M | 0,14% |
Total ekuitas | 7,55 M | — |
Saham yang beredar | 680,51 jt | — |
Harga terhadap nilai buku | 1,22 | — |
Tingkat pengembalian aset | 4,81% | — |
Tingkat pengembalian modal | 5,53% | — |
Arus Kas
Perubahan kas bersih
| (EUR) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | 126,96 jt | 145,62% |
Kas dari operasi | 325,40 jt | 8,61% |
Kas dari investasi | -122,68 jt | 37,53% |
Kas dari pembiayaan | -138,76 jt | 91,08% |
Perubahan kas bersih | 62,27 jt | 104,24% |
Arus kas bebas | 369,19 jt | 37,66% |
Tentang
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
CEO
Didirikan
18 Nov 1940
Situs
Karyawan
23.800